Pipeline at a glance

 

We strongly believe the future of Oncology resides in providing patients with personalized treatments based on individual cancer care. To answer this challenge, we have been building a diversified and innovative portfolio that focuses on small molecules, engineered antibodies, and cell therapy for the treatment of both hematological malignancies and solid tumors.

Our burgeoning pipeline includes:

– Eight new molecules in clinical development and

– Two New Molecular Entities (NMEs) in pre-clinical state: MCL-1 inhibitor and UCART 19

 

Name: Pixantrone

Description: Pixantrone (Pixuvri®) is licensed in the European Union in the field of multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphomas. It was originally developed by the US-based biotech company CTI BioPharma, with whom Servier has been in close partnership since 2014.

Additional link: European Medicines Agency (EMA)

Name: B-cell lymphoma 2 (Bcl-2) inhibitor

Description: Relapsed/Refractory Acute Myeloid Leukemia + Myelodysplastic Syndrome

Name: B-cell lymphoma 2 (Bcl-2) inhibitor

Description: Chronic Lymphocytic Leukemia

Name: Dual-Affinity Retargeting molecule (DART) CD3xCD123

Description: Acute Myeloid Leukemia + Myelodysplastic Syndrome

Name: Universal Chimeric Antigen Receptor T-cell (UCART) 19

Description: Acute Lymphoblastic Leukemia

Name: Universal Chimeric Antigen Receptor T-cell (UCART) 19

Description: Relapsed Refractory Diffuse Large B-cell Lymphoma

Name: Mono Polar Spindle (MPS) 1 inhibitor / proteine kinase TTK inhibitor

Description: Hematological malignancies

Name: Myeloid cell leukemia-1 (Mcl-1)
Description: R/R  Acute Myeloid Leukemia

Name: Myeloid cell leukemia-1 (Mcl-1)
Description: R/R  Multiple Myeloma

Name: Trifluridine/tipiracil

Description: Lonsurf is licensed in the European Union for the treatment of adult patients with metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents.

Additional link: European Medicines Agency (EMA)

Name: Trifluridine/tipiracil

Description: Gastric cancer 3rd line

Name: Trifluridine/tipiracil

Description: Metastatic colorectal cancer (CRC) 1st line

Name: Trifluridine/tipiracil

Description: Metastatic colorectal cancer (CRC) 2nd line

Name: Dual-Affinity Retargeting molecule (DART) CD3 x gpA33

Description: Metastatic colorectal cancer

Name: MET/AXL / Fibroblast Growth Factor Receptor (MET/AXL/FGFR) inhibitor

Description: Lung cancer

Name: Mono Polar Spindle (MPS) 1 inhibitor / proteine kinase TTK inhibitor

Description: Multiple – solid tumors

Name: Anti-PD-1mAb

Description: Solid tumors